This program reviews the latest developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for treatment decision making in the management of patients with non-small cell lung cancer.
This activity is intended for medical oncologists, thoracic surgeons, advanced practitioners, physician assistants, pulmonologists, radiologists, and other healthcare professionals involved in the treatment of patients with NSCLC.
Upon completion of this activity, participants will be able to:
- Assess and apply histologic considerations for maximizing the safety and benefit associated with chemotherapy and targeted agents in the treatment of patients with NSCLC.
- Evaluate recent studies investigating the utility of molecular markers as predictors of treatment response or resistance to specific agents and employ proven markers to develop individual treatment plans for patients with NSCLC.
- Discuss the role of maintenance therapy in the treatment of patients with NSCLC.
Statement of Need:
Lung cancer is the leading cause of cancer mortality in the United States, killing more American men and women than breast, prostate, colon, and pancreatic cancers combined. Last year, an estimated 88,000 men and 70,000 women died of lung cancer, which approaches a third of all cancer-related deaths. Although the incidence and mortality rates for lung cancer in men have dropped in the past decade, a similar trend has not occurred in women. The incidence rate of lung cancer in women is approaching a plateau after a long period of increase, reflecting historical differences in cigarette smoking between men and women. Since the early 1980s, more women have died of lung cancer than breast cancer, and lung cancer death rates for American women are now among the highest in the world.
Despite several decades of extensive research, the 5-year survival rate for all stages combined is only 15%. In this challenging and continually evolving treatment setting, careful selection of an appropriate treatment plan by considering patient characteristics and available data from clinical trials can significantly impact survival. Recent advancements include the development of novel targeted and chemotherapeutic agents, identification of tumor characteristics that are associated with benefit from distinct treatment regimens, and an emerging role for maintenance therapy in prolonging survival. After completing this activity, participants will be able to review emerging clinical trial data that evaluate the role of biomarker analyses in treatment decision making, assess histological considerations for maximizing the safety and benefit associated with chemotherapy and targeted agents, and discuss the role of maintenance therapy in the treatment of patients with non–small cell lung cancer (NSCLC).
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Nebraska Medical Center, Center for Continuing Education and oneconsortium™.
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Jeffrey Crawford, MD
George Barth Geller Professor for Research in Cancer
Chief, Division of Medical Oncology
Department of Medicine
Duke University Medical Center
Mark A. Socinski, MD
Professor of Medicine
Multidisciplinary Thoracic Oncology Program
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, NC
Everett E. Vokes, MD - Chair
John E. Ultmann Professor of Medicine and Radiation and Cellular Oncology
University of Chicago Medical Center
Jeffrey Crawford, MD
Advisory Board - Agennix, Amgen Inc.
Grant/Research Support - Agennix, Amgen Inc.
Honoraria - Genentech, Inc.; Lilly USA, LLC
Speaker’s Bureau - Amgen Inc.
Mark A. Socinski, MD
Grant/Research Support - Abraxis BioScience, LLC; Celgene Corporation; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Pfizer Inc.
Speaker’s Bureau - Genentech, Inc.; Lilly USA, LLC; sanofi-aventis
Everett E. Vokes, MD
Consultant - Amgen Inc.; Boehringer Ingelheim; Champions Biotechnology, Inc.; Genentech, Inc.; GlaxoSmithKline; ImClone Systems Incorporated; OSI Pharmaceuticals, Inc.; Poniard Pharmaceuticals, Inc.; Roche Diagnostics; sanofi-aventis
Honoraria - Amgen Inc.; Boehringer Ingelheim; Champions Biotechnology, Inc.; Genentech, Inc.; GlaxoSmithKline; ImClone Systems Incorporated; OSI Pharmaceuticals, Inc.; Poniard Pharmaceuticals, Inc.; Roche Diagnostics; sanofi-aventis
The following staff have declared they have no financial relationships that require disclosure:
Darren Casonhua, JD, Principal, oneconsortium™
Lois Colburn, Executive Director, University of Nebraska Medical Center, Center for Continuing Education
Claudia Low, PhD, Sr. Medical Writer, the CBCE
Christine M. O’Leary, PharmD, BCPS, Clinical Director, Institute for Continuing Healthcare Education
Cathy Pagano, President, Institute for Continuing Healthcare Education
Brenda Ram, CMP, Continuing Education Coordinator, University of Nebraska Medical Center, Center for Continuing Education
Donna Robillard, Educational Program Supervisor, the CBCE
John Ruggiero, PhD, MPA, CCMEP, Institute for Continuing Healthcare Education
George Witter, Senior Vice President, MedEd Architects LLC
Disclosure of Financial Relationships with Any Commercial Interest:
Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author, and cannot have control of or responsibility for the development, management, presentation, or evaluation of the educational activity. For an individual with no relevant financial relationship, participants must be informed that no relevant financial relationship exists.
Disclosure of Potential Conflicts of Interest:
The University of Nebraska Medical Center, Center for Continuing Education assesses conflicts of interest with its faculty, planners, and managers. Identified conflicts of interest are thoroughly evaluated for fair balance, scientific objectivity relative to studies utilized in this activity, and patient-care recommendations.
The University of Nebraska Medical Center, Center for Continuing Education; oneconsortium™ and the CBCE™ (The Center for Biomedical Continuing Education) receive educational grants from the pharmaceutical industry and other commercial sources. Companies providing grants include the commercial supporters of this activity as well as the manufacturers of certain drugs and/or devices discussed in this activity.
The University of Nebraska Medical Center, Center for Continuing Education and oneconsortium™ gratefully acknowledge the educational grants provided by Lilly USA, LLC and Pfizer Inc.
If you have any questions relating to the accreditation of this activity, please contact,
University of Nebraska Medical Center, Center for Continuing Education
986800 Nebraska Medical Center, Omaha, NE 68198-6800
Telephone: (402) 559-4152 Fax: (402) 559-5915
To receive a statement of credit, you must:
- Review each presentation in its entirety
- Complete the post test (achieving a minimum of 70% correct)
- Complete the activity evaluation/CME request form
- Print out certificate of credit
Your statement of credit will be issued immediately upon successful completion of the post-test and evaluation form.Disclaimer:
The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the University of Nebraska Medical Center, Center for Continuing Education; oneconsortium™; the CBCE; Lilly USA, LLC; or Pfizer Inc. This material has been prepared based on a review of multiple sources of information but is not comprehensive. Participants are advised to critically appraise the information presented, and they are encouraged to consult the available literature on any product or device mentioned in this program.Software Requirements:
To view the activities on this website, your computer needs to have Internet Explorer 6.0 (or higher) or Mozilla Firefox 2 (or higher) or Safari 2 (or higher) and Adobe Flash Player 9.0 (or higher). If you are using a modem to connect to the Internet, you will need a modem speed of at least 56K to view the pages of the site. Video content requires DSL and higher. Adobe Flash Player is required to complete the self-assessment and Adobe Reader is required to print your certificate. You can download Adobe Reader for free. As you will be printing your CME/CE certificate online, your computer must be connected to a printer.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.